文献速递脑血管病

REVASCAT试验1年随访:急性缺血性卒中取栓的疗效与安全性

Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial.
PubMed 文献 · Lancet Neurol · 2017-03-16

REVASCAT试验将症状出现8小时内可治疗的急性缺血性卒中患者随机分为药物联合Solitaire FR取栓组或单纯药物治疗组。12个月随访显示,取栓组改良Rankin量表(mRS)整体分布更优、功能独立比例更高、健康相关生活质量更佳,1年死亡率两组相近,提示获益持续存在。

要点

  • 两组1年死亡率相近:取栓组23%,对照组24%。

核心结论

  • 12个月随访时,神经血管取栓减轻卒中后残疾并改善健康相关生活质量,提示获益持续。

研究设计与样本

  • 入组为症状出现8小时内可治疗的急性缺血性卒中患者,取栓使用Solitaire FR装置,药物治疗在符合条件时包括静脉阿替普酶。
  • 12个月终点由设盲研究者评估,主要次要终点为mRS分布。

主要发现

  • 1年死亡率为取栓组23%(24/103例)对对照组24%(25/103例)。

关键数值与推荐

  • mRS范围0(无症状)至6(死亡),分析时将5(严重残疾)与6(死亡)合并为一类。

临床怎么用

  • 对症状出现8小时内可治疗的急性缺血性卒中患者,取栓的获益可维持至12个月,支持长期成本效果评估。

局限性

  • 开放标签设计,但12个月终点由设盲研究者评估;12个月结局206例中205例可获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The REVASCAT trial and other studies have shown that the neurovascular thrombectomy improves outcomes at 90 days post stroke. However, whether the observed benefit is sustained in the long term remains unknown. We report the results of the prespecified 12-month analysis of the REVASCAT trial. METHODS: Patients with acute ischaemic stroke who could be treated within 8 h of symptom onset were randomly assigned to medical therapy (including intravenous alteplase when eligible) and neurovascular thrombectomy with Solitaire FR or medical therapy alone. The main secondary outcome measure at 1 year follow-up was disability, measured using the modified Rankin Scale (mRS), ranging from 0 (no symptoms) to 6 (death) with categories 5 (severe disability) and 6 (death) collapsed into one category (severe disability or death), analysed as the distribution of the mRS. Additional prespecified secondary outcome measures included health-related quality of life measured with the EuroQol five dimensions questionnaire (EQ-5D) utility index (ranging from -0·3 to 1, higher values indicate better quality of life), the rate of functional independence (mRS 0-2), and cognitive function measured with the Trail Making Test (reported elsewhere). Treatment allocation was open label but endpoints at 12 months were assessed by masked investigators. The trial was registered at ClinicalTrials.gov, number NCT01692379. FINDINGS: From Nov 24, 2012, to Dec 12, 2014, 206 patients were randomly assigned to medical therapy plus endovascular treatment (n=103) or medical treatment alone (n=103), at four centres in Catalonia, Spain. At 12 months post randomisation, based on 205 of 206 outcomes available at 12 months, thrombectomy reduced disability over the range of the mRS (common adjusted odds ratio [aOR] 1·80, 95% CI 1·09-2·99), and improved functional independence (mRS=0-2; 45 [44%] of 103 patients vs 31 [30%] of 103 patients; aOR 1·86, 95% CI 1·01-3·44). Health-related quality of life was superior in the thrombectomy group (mean EQ-5D utility index score, 0·46 [SD 0·38] in the thrombectomy group vs 0·33 [0·33] in the control group, difference 0·12 [95% CI 0·03-0·22]; p=0·01). 1-year mortality was 23% (24 of 103 patients) in the thrombectomy group versus 24% (25 of 103 patients) in the control group. INTERPRETATION: At 12 months follow-up, neurovascular thrombectomy reduced post-stroke disability and improved health-related quality of life, indicating sustained benefit. These findings have important clinical and public health implications for evaluating the cost-effectiveness of the intervention in the long term. FUNDING: Fundació Ictus Malaltia Vascular through an unrestricted grant from Medtronic.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Dávalos A, Cobo E, Molina CA, et al. Safety and efficacy of thrombectomy in acute ischaemic stroke (REVASCAT): 1-year follow-up of a randomised open-label trial. Lancet Neurol. 2017. PMID: 28318984. doi:10.1016/S1474-4422(17)30047-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。